Compugen Advances COM503 to Phase 1 Clinical Trial in Cancer Treatment

TipRanksJan 8 20:28

Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead

BenzingaJan 8 20:04

The Past Five Years for Compugen (NASDAQ:CGEN) Investors Has Not Been Profitable

Yahoo FinanceDec 26, 2024 21:01

Compugen Bolsters Cancer Therapy Portfolio With New Patent

TipRanksNov 27, 2024 20:32

Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies

BenzingaNov 27, 2024 20:03

Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial

Seeking AlphaNov 26, 2024 19:53